论文部分内容阅读
目的:回顾性分析比较CsA(cyclosporine A)联合司坦唑醇方案及司坦唑醇联合再障生血片方案治疗儿童慢性型再生障碍性贫血(CAA)的临床疗效差异。方法:根据不同治疗方案将64例CAA患儿分为Ⅰ组(CsA+司坦唑醇治疗组)38例、Ⅱ组(司坦唑醇+再障生血片blood-engendering tablet治疗组)26例,参照中华医学会儿科分会血液学组小儿再生障碍性贫血诊疗建议的疗效评定标准,运用SPSS17.0统计软件进行两组间临床基本有效率、总有效率及起效时间、血象恢复程度比较。结果:Ⅰ组患儿的基本治愈率、总有效率和血象恢复程度均高于Ⅱ组,差异有统计学意义(P<0.05);Ⅰ组平均起效时间短于Ⅱ组,差异有统计学意义(P<0.05)。两组不良反应均轻微。结论:CsA联合司坦唑醇的免疫抑制疗法方案治疗儿童CAA起效快、疗效更优,相对安全,值得在临床推广。
OBJECTIVE: To retrospectively analyze the difference of clinical efficacy between cyclosporine A combined with stanozolol and stanozolol combined with EPBD in children with chronic aplastic anemia (CAA). Methods: Sixty-four patients with CAA were divided into group I (CsA + stanozolol treatment group) 38 cases and group II (stanzolol + bHD group blood-engendering tablet treatment group) according to the different treatment regimens. Reference to the Chinese Medical Association Pediatrics Hematology pediatric aplastic anemia treatment recommendations of the evaluation criteria, the use of SPSS17.0 statistical software for clinical basic efficiency, the total effective rate and onset time, the degree of recovery of blood compared. Results: The basic cure rate, total effective rate and the degree of blood picture recovery in group Ⅰ were higher than that in group Ⅱ, the difference was statistically significant (P0.05); the average onset time in group Ⅰ was shorter than that in group Ⅱ Significance (P <0.05). Adverse reactions were mild in both groups. Conclusion: CsA combined with stanozolol immunosuppressive regimen in children with CAA rapid onset, better efficacy, relatively safe, it is worth in the clinical promotion.